^
Association details:
| Biomarker: | EML4-ALK fusion + ALK F1174L + ALK S1189C |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
Published date:
11/23/2022
Excerpt:
Pathological analysis of bronchoscopy biopsy tissue confirmed lung adenocarcinoma….The presence of EML4-ALK gene fusion and an ALK exon 23 F1174L and S1189C mutation was identified by targeted next-generation sequencing...The patient received crizotinib (250 mg, BID) as first-line targeted therapy for approximately 2.5 months...progressive disease (PD) was diagnosed according to chest CT...
DOI:
https://doi.org/10.3389/fphar.2022.1060460
